Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres.

Smith SD, Moskowitz CH, Dean R, Pohlman B, Sobecks R, Copelan E, Andresen S, Bolwell B, Maragulia JC, Vanak JM, Sweetenham J, Moskowitz AJ.

Br J Haematol. 2011 May;153(3):358-63. doi: 10.1111/j.1365-2141.2011.08616.x. Epub 2011 Mar 16.

PMID:
21410449
2.

How I treat relapsed and refractory Hodgkin lymphoma.

Kuruvilla J, Keating A, Crump M.

Blood. 2011 Apr 21;117(16):4208-17. doi: 10.1182/blood-2010-09-288373. Epub 2011 Jan 24.

3.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A.

N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.

4.

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

Jona A, Younes A.

Blood Rev. 2010 Nov;24(6):233-8. doi: 10.1016/j.blre.2010.08.003. Epub 2010 Sep 15. Review.

5.

Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.

Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM.

Leuk Lymphoma. 2010 Jul;51(7):1251-9. doi: 10.3109/10428194.2010.486090.

PMID:
20528244
6.

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M.

J Clin Oncol. 2009 Sep 20;27(27):4548-54. doi: 10.1200/JCO.2008.19.8820. Epub 2009 Aug 24.

7.

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK.

Br J Haematol. 2009 Jul;146(2):171-9. doi: 10.1111/j.1365-2141.2009.07740.x. Epub 2009 May 19.

PMID:
19466965
8.

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.

Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z, Vanak J, Zelenetz AD, Moskowitz CH.

Br J Haematol. 2009 Jul;146(2):158-63. doi: 10.1111/j.1365-2141.2009.07727.x. Epub 2009 May 12.

9.

Management of Hodgkin lymphoma in relapse after autologous stem cell transplant.

Crump M.

Hematology Am Soc Hematol Educ Program. 2008:326-33. doi: 10.1182/asheducation-2008.1.326.

PMID:
19074105
10.

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW.

Ann Oncol. 2008 Oct;19(10):1759-64. doi: 10.1093/annonc/mdn365. Epub 2008 May 25.

11.

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A.

Ann Oncol. 2008 Jul;19(7):1312-9. doi: 10.1093/annonc/mdn052. Epub 2008 Mar 19.

12.

Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.

David KA, Mauro L, Evens AM.

Curr Treat Options Oncol. 2007 Oct;8(5):352-74. doi: 10.1007/s11864-007-0046-9. Review.

PMID:
18214690
13.

Risk, cure and complications in advanced hodgkin disease.

Horning SJ.

Hematology Am Soc Hematol Educ Program. 2007:197-203. Review.

PMID:
18024630
14.

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers B, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A.

Biol Blood Marrow Transplant. 2007 May;13(5):594-600. Epub 2007 Mar 23.

15.

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.

Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ.

Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72.

16.

High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.

Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM.

J Clin Oncol. 2005 Nov 1;23(31):7994-8002. Epub 2005 Oct 3.

17.

State-of-the-art therapeutics: Hodgkin's lymphoma.

Connors JM.

J Clin Oncol. 2005 Sep 10;23(26):6400-8. Review.

PMID:
16155026
18.

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ.

Blood. 2005 Aug 15;106(4):1473-8. Epub 2005 May 3.

19.

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.

Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Holowiecki J, Gozdzik J, Hansz J, Avigdor A, Nagler A, Osowiecki M, Walewski J, Mensah P, Jurczak W, Skotnicki A, Sedzimirska M, Lange A, Sawicki W, Sulek K, Wach M, Dmoszynska A, Kus A, Robak T, Warzocha K.

Ann Oncol. 2004 Aug;15(8):1222-30.

20.

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.

Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE.

Bone Marrow Transplant. 2004 May;33(10):1015-23.

PMID:
15048145
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk